Kornimate/medical-research-clean huggingface dataset:
chest physiotherapy after bariatric aurgery - a comparison between incentive spirometry and expiratory positive airway pressure (epap)

Conditions: Obesity

Summary: objective: to compare the effects of the epap and the incentive spirometry flow-oriented in the pulmonary function after bariatric surgery. method: twenty-eight women, non-smokers, with no lung disease and bmi of 35-49,99 kg/m2, undergoing bariatric surgery by laparoscopy, were studied. before surgery the patients were divided in two groups: spirometer group (sg) (n=13) and epap group (eg) (n=15). pulmonary function was evaluated by spirometry, thoracoabdominal (cirtometry) and diaphragmatic motion, on the preoperative and on the second postoperative day. physiotherapy started on the day of surgery, each modality (incentive spirometry or epap) performed lasting 15 minutes. the deambulation and active exercises of upper and lower limbs were standardized for groups.


Eligibility criteria:
inclusion criteria: * obese with body mass index between: 35 e 50 kg/m2 * non-smokers * no lung disease exclusion criteria: * unable to perform the evaluation tests * not signed the consentment term

Keywords: physiotherapy breathing exercises bariatric surgery laparoscopy
smart phone application in the secondary clinical prevention management for chinese patients

Conditions: Coronary Disease

Summary: the purpose of the study is to investigate the effects of smart phone app on the secondary prevention for patients with coronary heart disease post percutaneous coronary intervention.

the secondary prevention for patients with coronary heart disease post percutaneous coronary intervention (pci) proved associated with a significant reduction in mortality rates and improvement in quality of life. for the limitation of socio-economic conditions, not all patients post pci are in a position to receive continuous standardized secondary prevention management. therefore a smart phone app for secondary prevention management post pci will be installed on patients' smart phones in order to investigate its effects on risk factors control, medication compliance, as well as quality of life and adverse cardiac events in the next six months post discharge. participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary heart disease. patients in app group and control group will be interviewed by telephone at the 2nd week and the 3rd month, and at the 1st month and 6th month they will return our hospital for face to face follow-up and to compliance and medication adjustment, assessment of life quality, risk factors control and medication adherence.

Eligibility criteria:
inclusion criteria: * first diagnosis of coronary heart disease and received a pci treatment. * age 18-65 years. * able and willing to provide written informed consent. exclusion criteria: * speech communication barriers. * patients with a clear history of allergies to anti-platelet drugs. * patients with a clear history of allergies to anti-platelet ᵦ-blockers. * patients with a clear history of allergies to statin drugs. * patients with a clear history of allergies to antihypertensive drugs. * patients with a clear history of allergies to antidiabetic drugs. * patients with serious heart failure(better than nyha class ii). * patients with cerebral infarction or cerebral hemorrhage. * patients with liver dysfunction (ast and alt\> 2 times that of the reference value). * patients with kidney dysfunction (creatinine clearance rate\< 60ml/min).

Keywords: coronary disease percutaneous coronary intervention secondary prevention smart phone app
comparative analysis of isolated venous, isolated arterial, and standard access for transcatheter closure of patent ductus arteriosus (pda)

Conditions: Hemodynamically Significant PDA

Summary: we enrolled all patients with a hemodynamically significant pda demonstrated by patient clinical condition, and by pda size \& left chamber dilatation on echocardiography attending at cardiology department to we compare the use of a single venous access and a single arterial access with the standard approach requiring both venous and arterial access for transcatheter pda closure regarding the outcome \& complications.


Eligibility criteria:
inclusion criteria: * any patient with hemodynamically significant pda exclusion criteria: * patient with pulmonary hypertension and eisenmenger syndrome
postoperative symptoms in chinese liver cancer patients: network analysis

Conditions: Patients With Primary Liver Cancer (PLC) Undergoing Curative Surgical Procedures; Importance of Identifying Core Symptoms for Improving Symptom Management in PLC Patients; Application of Network Analysis as a Crucial Component of Cancer Care

Summary: patients with primary liver cancer (plc) experience a range of symptoms in the early postoperative period. symptoms include cancer-related symptoms and adverse effects of treatment. exploring the core symptoms and their dynamics in the early post-hepatectomy patients may help provide better symptom management programs. the purpose of this study was to identify the core symptoms in early post-hepatectomy patients and to explore the trajectory of their dynamics. during the period from march 2021 to september 2022, a total of 281 patients diagnosed with plc and undergoing radical curative surgery were recruited from the hepatobiliary surgery departments of two hospitals in eastern china, among whom 249 individuals (88.60%) agreed to participate in the study. a comprehensive symptom assessment was administered to the patients 1-2 days after surgery (t1) and 1-2 days before discharge (t2). network analysis was used to identify core symptoms in early post-hepatectomy patients based on symptom severity.


Eligibility criteria:
inclusion criteria: * eligible patients were ≥18 years of age; had a diagnosis of primary liver cancer based on pathologic examination; were receiving the first hepatectomy; were conscious, spoke chinese, and had basic communication skills. exclusion criteria: * exclusion criteria include concurrent malignant tumors, mental disorders, or consciousness impairments, as well as participation in other clinical interventions.

Keywords: cancer liver hepatectomy network analysis symptom burden
effect of resistance and aerobic exercise in cidp or mmn

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor Neuropathy

Summary: resistance and aerobic exercise has been shown to be effective for maintenance of muscle strength in patients with neuromuscular diseases. exercise in cidp and mmn is sparsely described. the aim of the study is to evaluate changes in muscle strength during high intensive resistance training and changes in maximal oxygen consumption (vo2-max) during high intensive aerobic training in patients with cidp or mmn in maintenance therapy with subcutaneous immunoglobulin. the hypotheses are that muscle strength and vo2-max are significantly increased during the training sessions.


Eligibility criteria:
inclusion criteria: * age \> 18 and \< 80 years * diagnosed with definite or probable cidp or definite or probable mmn fulfilling the european federation of neurological sciences/peripheral nerve society (efns/pns) criteria * stable maintenance therapy with immunoglobulin (no change of dosage \< 3 months before inclusion) * duration of cidp or mmn \> 6 months * negative result on a pregnancy test (hcg-based assay in urine) for women of childbearing potential and use of a reliable method of contraception for the duration of the study exclusion criteria: * other cause of neuropathy (incl. pressure neuropathy) * exercise before enrolment (\> 1 hour of exercise per week or \> 4 km bicycling per day) * walking distance \< 10 meter with or without aid * diabetes mellitus, severe cardiac or pulmonary disease, malignancies * known history of adverse reactions to immunoglobulin a in other products * ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products. * history of malignancies of lymphoid cells and immunodeficiency with lymphoma * known liver function impairment (alat 3 times above upper limit of normal) * known protein-losing enteropathies or proteinuria. * known of renal function impairment (creatinine \>120 micromol/l or creatinine \>1.35 mg/dl), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs). * treatment with any investigational medicinal product within 3 months prior to first infusion of gammanorm * known or suspected hiv, hepatitis virus c or b infection * pregnant or nursing women * planned pregnancy during course of the study

Keywords: resistance training aerobic exercise isokinetic muscle strength bicycle ergometry test subcutaneous immunoglobulin
tmc125-c223: tmc125 in hiv-1 infected subjects

Conditions: HIV Infection

Summary: the purpose of this study is to investigate the ability of tmc125, a non-nucleoside reverse transcriptase inhibitor (nnrti), to lower the amount of virus in your blood when administered twice daily for 48 weeks.

tmc125 will be given in addition to a combination of anti-hiv drugs that have been selected specifically for you by your doctor. there are three treatment groups in the study. one group will be given a dosage of tmc125, 400 mg twice daily. another will be given 800 mg twice daily. the third group, a control arm, will not receive tmc125 (formulation tf035). the safety, tolerability and pharmacokinetics (determinations of the concentration of drug in your blood and its evolution over time) of tmc125 will also be evaluated in this study. patients who have known resistance to nnrtis and 3 or more protease inhibitor (pi) mutations may be eligible to participate. one-hundred-fifty (150) patients will be enrolled into this study. tmc125, 400mg twice daily for 48 weeks; tmc125, 800mg twice daily for 48 weeks.

Eligibility criteria:
inclusion criteria: * hiv-1 plasma viral load at screening \>1000 copies/ml * documented genotypic evidence of resistance to currently available nnrtis * previous nrti experience for at least 3 months * 3 primary pi mutations at screening exclusion criteria: * chronic hbv and/or hcv with elevated liver function tests \> 3x upper normal limits * any grade 3 or 4 toxicity according to the actg grading severity list (except for grade 3 glucose and asymptomatic triglyceride/cholesterol grade 3 or 4 elevation) * previous permanent discontinuation of any nnrti due to cutaneous events.

Keywords: hiv infection tmc125 non-nucleoside reverse transcriptase inhibitor, tmc125-c223
comparison of bupivacaine and exparel for carpal tunnel release

Conditions: Pain After Carpal Tunnel Release

Summary: carpal tunnel syndrome is one of the most common surgeries performed per year in the united states, accounting for over 600,000 surgeries. the procedure is commonly performed under light sedation and local anesthesia. bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. by decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase. the purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.


Eligibility criteria:
inclusion criteria: * patients with carpal tunnel syndrome undergoing surgery exclusion criteria: * non english speaking * allergy to bupivacaine or exparel
avatrombopag for the treatment of chemotherapy-induced thrombocytopenia in adults with active non-hematological cancers

Conditions: Chemotherapy-induced Thrombocytopenia

Summary: phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.

subjects will receive placebo controlled test treatment for one cycle of chemotherapy followed by an observational cycle. subjects will have the option to continue into an open label extension period for all remaining chemotherapy cycles within the current regimen. after the follow-up visit, all subjects will continue to a long-term safety follow-up period.

Eligibility criteria:
inclusion criteria: * men and women greater than or equal to 18 years of age; * a diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy * participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents: * nucleoside analog, including gemcitabine and fluorouracil; * carboplatin or cisplatin; * anthracycline; or * alkylating agent; * participant experienced severe thrombocytopenia, defined as 2 platelet counts \<50 x 109/l measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen * ecog performance status \<=2 exclusion criteria: * participant has experienced \>=grade 2 cit other than during the current chemotherapy treatment regimen within 6 months of screening; * participant has any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases; * participant has received \>2 previous lines of chemotherapy or is receiving whole brain radiation during the study treatment period; * participant has a known medical history of genetic prothrombotic syndromes * participant has a history of arterial or venous thrombosis within 3 months of screening; * use of vitamin k antagonists; * participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of cit within 3 months of screening

Keywords: cit thrombocytopenia
study on classification method of indocyanine green lymphography based on deep learning

Conditions: Breast Cancer Related Lymphedema; Deep Learning

Summary: breast cancer related lymphedema (bcrl) is the most common complication after breast cancer surgery, which brings a heavy psychological and spiritual burden to patients. for a long time, the diagnosis and treatment of lymphedema has been a difficult point in domestic and foreign research. to a large extent, it is because most of the patients who come to see a doctor have already developed obvious lymphedema, and the internal lymphatic vessels have undergone pathological remodeling\[1\] therefore, it is particularly important to detect early lymphedema and intervene in time through the use of sensitive screening tools. indocyanine green (icg) lymphangiography is a relatively new method, which can display superficial lymph flow in real time and quickly, and will not be affected by radioactivity \[7\]. in 2007, indocyanine green lymphography was used for the first time to evaluate the function of superficial lymphatic vessels. in 2011, japanese scholars found skin reflux signs based on icg lymphography data of 20 patients with lymphedema after breast cancer surgery, and they were roughly divided into three types according to their severity: splash, star cluster, and diffuse (figure 1) \[8\]. later, in 2016, a prospective study involving 196 people affirmed the value of icg lymphography in the early diagnosis of lymphedema, and made the images of icg lymphography more specific stages 0-5 \[9\], but the staging is still based on the three types of skin reflux symptoms found in a small sample clinical study in 2011, which is not completely applicable in actual clinical applications. in addition, when abnormal skin reflux symptoms appear on icg lymphangiography, the pathophysiological changes that occur in the body lack research and exploration. therefore, this research hopes to refine the image features of icg lymphography through machine learning (deep learning), and establish a pkuph model for diagnosing early lymphedema by staging the image features.


Eligibility criteria:
inclusion criteria: * from october 2016 to present, about 200 patients who have been admitted to the breast surgery clinic due to the main complaint of upper extremity edema, are willing to accept icg lymphography, arm circumference measurement, drainage measurement, bioelectrical impedance measurement, main complaint scale, etc. . exclusion criteria: * bilateral breast cancer; history of contrast agent allergy; arteriovenous thrombosis in the affected limb; regional lymph node recurrence; no informed consent; severe heart and brain diseases; primary lymphatic system disease (such as lymphatic leakage); unilateral only the limbs received icg imaging.
diabetes care management trial of telemetric monitoring

Conditions: Diabetes

Summary: the study is a two-arm, parallel-comparison, single-blind, randomized controlled trial, and will be offered to kaiser permanente members aged 18 - 75 years old who present to the santa rosa diabetes care management center with type 2 diabetes mellitus. participants will be randomly assigned to one of two treatment arms. the telemedicine group or the group receiving usual care (the control group). this study hopes to show the usefulness of this telemonitoring technology and more specifically, to assess whether this device improves markers of control of diabetes, glycemic control, and cardiovascular risk factors


Eligibility criteria:
inclusion criteria: * 18 - 75 years old, * diagnosis of type 2 diabetes mellitus for at least 1 month, * eligible for and referred to the diabetes care management program, * hba1c values in the range: 7.5% to 10.5%. exclusion criteria: * weight \> 330 lbs, * estimated glomerular filtration rate (gfr) \< 45, * unstable coronary artery disease, * severe peripheral vascular disease which restricted exercise, * end-stage liver disease, * undergoing treatment for cancer, * pregnant or not using appropriate birth control, * no broadband internet access in their homes.

Keywords: diabetes hba1c fructosamine blood pressure telemonitoring
body warming in improving blood flow and oxygen delivery to tumors in patients with cancer

Conditions: Adult Liver Carcinoma; Breast Carcinoma; Colon Carcinoma; Kidney Neoplasm; Lung Carcinoma; Malignant Head and Neck Neoplasm; Malignant Neoplasm; Melanoma; Ovarian Neoplasm; Soft Tissue Sarcoma

Summary: this randomized pilot clinical trial studies body warming in improving blood flow and oxygen delivery to tumors in patients with cancer. heating tumor cells to several degrees above normal body temperature may kill tumor cells.

primary objectives: i. to determine the feasibility and efficacy of 2 different body warming to alter (thermo) regulation and the microenvironment (b-warm) regimens on altering tumor blood flow in patients with a variety of malignancies. secondary objectives: i. to determine if duration and thermal dose of b-warm changes duration and extent of tumor blood flow changes in patients with a variety of malignancies. outline: patients are randomized to 1of 2 arms. arm i: patients undergo b-warm at 39 degrees celsius (c) for 30 minutes. arm ii: patients undergo b-warm at 39 degrees c for 2 hours. after completion of study, patients are followed up at 30 days.

Eligibility criteria:
inclusion criteria: * patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and neck, renal, breast, lung, ovary, liver) * patients must have measurable disease (1.0 cm or greater) by computed tomography (ct) scan * have an estimated glomerular filtration rate (egfr) (using the cockcroft-gault equation) of more than 60 ml/min * have an eastern cooperative oncology group (ecog) performance status of 0-2 * patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment * patient or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure exclusion criteria: * history of prior myocardial infarction or arrhythmia * history of any condition deemed by the principal investigator to be a contraindication to b-warm therapy (e.g., skin reaction, dysregulation of thermoregulation, etc) * all patients with transdermal patches (e.g.; fentanyl, lidoderm, scopolamine, etc) * pregnant or nursing female patients * unwilling or unable to follow protocol requirements * any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive b-warm * received an investigational agent within 30 days prior to enrollment * received any systemic therapy within 21 days prior to planned b-warm therapy * patients may be enrolled on study but at least 21 days should elapse prior to date of b-warm therapy * patients should not have either ct scanning or b-warm if they have a fever at the time * fever should be worked up and treated as appropriate * patients should be afebrile for 24 hours prior to scanning or b-warm therapy
physical activity and preterm birth with cervical dynamics

Conditions: Preterm Birth

Summary: this rct is designed to investigate the influence of physical activity on the risk f preterm birth for women with cervical dynamics.


Eligibility criteria:
inclusion criteria: pregnant women between 24-34 weeks of gestation singleton cervical length\<25 mm willing to download an application which traces physical activity on medical indication for reducing activity exclusion criteria: refusal to participate medical advise to minimize activity (symphysiolysis) maternal morbidity fetal compromise vaginal bleeding rapture of membranes severe preeclampsia twins pregnancy -
coronary cto pci using antegrade wiring strategy with a first-choice gladius guidewire (gladius first)

Conditions: Coronary Artery Disease; Coronary Occlusion; Percutaneous Coronary Intervention

Summary: the gladius first trial is designed as a single-centre, open, prospective, randomized clinical trial aimed to assess the efficiency and safety of coronary chronic total occlusion (cto) percutaneous coronary intervention (pci) using the antegrade wiring strategy with a first-choice intermediate gladius guidewire. to this end, consecutive patients referred to cto pci with intended primary antegrade wire escalation strategy, will be randomized in a 1:1 fashion to antegrade wiring starting with the gladius guidewire or antegrade wiring using the standard guidewire escalation strategy.


Eligibility criteria:
inclusion criteria: * delivery of an informed consent and compliance with study protocol * cto of a major coronary artery with at least intermediate difficulty score (j-cto ≥1) as assessed by invasive angiography * referral to clinically indicated cto pci with intended primary antegrade wiring strategy exclusion criteria: * in-stent cto * unstable angina and/or myocardial infarction * prior myocardial infarction within 4 weeks before study enrolment * cto of a major coronary artery with an easy difficulty score (j-cto 0) as assessed by invasive coronary angiography * lack of valid antegrade wire escalation strategy as assessed by 2 independent cto pci operators * chronic kidney disease (defined as egfr ≤30 ml/min/m2) * contraindication to antiplatelet therapy and/or heparin * severe inflammatory disease * positive pregnancy test or breast-feeding